![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HTT |
Gene summary for HTT |
![]() |
Gene information | Species | Human | Gene symbol | HTT | Gene ID | 3064 |
Gene name | huntingtin | |
Gene Alias | HD | |
Cytomap | 4p16.3 | |
Gene Type | protein-coding | GO ID | GO:0000132 | UniProtAcc | P42858 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3064 | HTT | LZE7T | Human | Esophagus | ESCC | 3.73e-09 | 3.57e-01 | 0.0667 |
3064 | HTT | LZE8T | Human | Esophagus | ESCC | 3.31e-02 | 4.78e-02 | 0.067 |
3064 | HTT | LZE20T | Human | Esophagus | ESCC | 2.39e-07 | 1.87e-01 | 0.0662 |
3064 | HTT | LZE22T | Human | Esophagus | ESCC | 1.72e-02 | 1.49e-01 | 0.068 |
3064 | HTT | LZE24T | Human | Esophagus | ESCC | 1.72e-04 | 1.04e-01 | 0.0596 |
3064 | HTT | LZE21T | Human | Esophagus | ESCC | 3.01e-03 | 1.80e-01 | 0.0655 |
3064 | HTT | P1T-E | Human | Esophagus | ESCC | 1.49e-02 | 1.30e-01 | 0.0875 |
3064 | HTT | P2T-E | Human | Esophagus | ESCC | 3.66e-22 | 3.86e-01 | 0.1177 |
3064 | HTT | P4T-E | Human | Esophagus | ESCC | 5.81e-10 | 1.49e-01 | 0.1323 |
3064 | HTT | P5T-E | Human | Esophagus | ESCC | 7.74e-06 | 3.34e-02 | 0.1327 |
3064 | HTT | P8T-E | Human | Esophagus | ESCC | 9.31e-18 | 2.46e-01 | 0.0889 |
3064 | HTT | P9T-E | Human | Esophagus | ESCC | 3.09e-09 | 1.41e-01 | 0.1131 |
3064 | HTT | P10T-E | Human | Esophagus | ESCC | 2.76e-06 | 1.09e-01 | 0.116 |
3064 | HTT | P11T-E | Human | Esophagus | ESCC | 2.27e-04 | 1.92e-01 | 0.1426 |
3064 | HTT | P12T-E | Human | Esophagus | ESCC | 1.60e-14 | 1.35e-01 | 0.1122 |
3064 | HTT | P15T-E | Human | Esophagus | ESCC | 3.77e-07 | 6.69e-02 | 0.1149 |
3064 | HTT | P16T-E | Human | Esophagus | ESCC | 2.43e-08 | 1.38e-01 | 0.1153 |
3064 | HTT | P17T-E | Human | Esophagus | ESCC | 3.01e-08 | 2.41e-01 | 0.1278 |
3064 | HTT | P19T-E | Human | Esophagus | ESCC | 8.63e-06 | 3.02e-01 | 0.1662 |
3064 | HTT | P20T-E | Human | Esophagus | ESCC | 1.23e-04 | 6.66e-02 | 0.1124 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
GO:00108227 | Oral cavity | OSCC | positive regulation of mitochondrion organization | 53/7305 | 74/18723 | 1.26e-08 | 2.55e-07 | 53 |
GO:000689010 | Oral cavity | OSCC | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 40/7305 | 52/18723 | 2.86e-08 | 5.50e-07 | 40 |
GO:00516489 | Oral cavity | OSCC | vesicle localization | 105/7305 | 177/18723 | 3.30e-08 | 6.30e-07 | 105 |
GO:19021155 | Oral cavity | OSCC | regulation of organelle assembly | 109/7305 | 186/18723 | 4.54e-08 | 8.45e-07 | 109 |
GO:003070510 | Oral cavity | OSCC | cytoskeleton-dependent intracellular transport | 113/7305 | 195/18723 | 6.03e-08 | 1.09e-06 | 113 |
GO:003530319 | Oral cavity | OSCC | regulation of dephosphorylation | 80/7305 | 128/18723 | 6.10e-08 | 1.10e-06 | 80 |
GO:003530420 | Oral cavity | OSCC | regulation of protein dephosphorylation | 60/7305 | 90/18723 | 9.75e-08 | 1.67e-06 | 60 |
GO:005165120 | Oral cavity | OSCC | maintenance of location in cell | 121/7305 | 214/18723 | 1.39e-07 | 2.32e-06 | 121 |
GO:00105087 | Oral cavity | OSCC | positive regulation of autophagy | 77/7305 | 124/18723 | 1.59e-07 | 2.61e-06 | 77 |
GO:00070307 | Oral cavity | OSCC | Golgi organization | 92/7305 | 157/18723 | 4.96e-07 | 7.27e-06 | 92 |
GO:200123720 | Oral cavity | OSCC | negative regulation of extrinsic apoptotic signaling pathway | 60/7305 | 97/18723 | 4.31e-06 | 4.98e-05 | 60 |
GO:00109706 | Oral cavity | OSCC | transport along microtubule | 88/7305 | 155/18723 | 5.35e-06 | 6.02e-05 | 88 |
GO:003001016 | Oral cavity | OSCC | establishment of cell polarity | 82/7305 | 143/18723 | 6.56e-06 | 7.24e-05 | 82 |
GO:00723845 | Oral cavity | OSCC | organelle transport along microtubule | 53/7305 | 85/18723 | 1.10e-05 | 1.14e-04 | 53 |
GO:000961210 | Oral cavity | OSCC | response to mechanical stimulus | 115/7305 | 216/18723 | 1.43e-05 | 1.44e-04 | 115 |
GO:00619127 | Oral cavity | OSCC | selective autophagy | 44/7305 | 68/18723 | 1.57e-05 | 1.57e-04 | 44 |
GO:003134610 | Oral cavity | OSCC | positive regulation of cell projection organization | 176/7305 | 353/18723 | 1.94e-05 | 1.87e-04 | 176 |
GO:19031469 | Oral cavity | OSCC | regulation of autophagy of mitochondrion | 25/7305 | 33/18723 | 1.95e-05 | 1.87e-04 | 25 |
GO:006049110 | Oral cavity | OSCC | regulation of cell projection assembly | 100/7305 | 188/18723 | 5.27e-05 | 4.38e-04 | 100 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05016210 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
hsa0501638 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
hsa0502238 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
hsa0501622 | Liver | HCC | Huntington disease | 219/4020 | 306/8465 | 3.06e-18 | 3.42e-16 | 1.90e-16 | 219 |
hsa0502222 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
hsa0501632 | Liver | HCC | Huntington disease | 219/4020 | 306/8465 | 3.06e-18 | 3.42e-16 | 1.90e-16 | 219 |
hsa0502232 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
hsa0501628 | Oral cavity | OSCC | Huntington disease | 204/3704 | 306/8465 | 1.70e-16 | 7.13e-15 | 3.63e-15 | 204 |
hsa0502228 | Oral cavity | OSCC | Pathways of neurodegeneration - multiple diseases | 292/3704 | 476/8465 | 1.60e-15 | 4.47e-14 | 2.28e-14 | 292 |
hsa05016112 | Oral cavity | OSCC | Huntington disease | 204/3704 | 306/8465 | 1.70e-16 | 7.13e-15 | 3.63e-15 | 204 |
hsa05022112 | Oral cavity | OSCC | Pathways of neurodegeneration - multiple diseases | 292/3704 | 476/8465 | 1.60e-15 | 4.47e-14 | 2.28e-14 | 292 |
hsa0502245 | Oral cavity | EOLP | Pathways of neurodegeneration - multiple diseases | 110/1218 | 476/8465 | 1.09e-07 | 1.26e-06 | 7.40e-07 | 110 |
hsa0501645 | Oral cavity | EOLP | Huntington disease | 69/1218 | 306/8465 | 6.32e-05 | 2.96e-04 | 1.75e-04 | 69 |
hsa0502255 | Oral cavity | EOLP | Pathways of neurodegeneration - multiple diseases | 110/1218 | 476/8465 | 1.09e-07 | 1.26e-06 | 7.40e-07 | 110 |
hsa0501655 | Oral cavity | EOLP | Huntington disease | 69/1218 | 306/8465 | 6.32e-05 | 2.96e-04 | 1.75e-04 | 69 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HTT | SNV | Missense_Mutation | novel | c.6190N>G | p.Leu2064Val | p.L2064V | P42858 | protein_coding | tolerated(0.12) | benign(0.058) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
HTT | SNV | Missense_Mutation | c.7393N>A | p.Glu2465Lys | p.E2465K | P42858 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
HTT | SNV | Missense_Mutation | rs776464028 | c.4827N>C | p.Gln1609His | p.Q1609H | P42858 | protein_coding | deleterious(0) | possibly_damaging(0.781) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
HTT | SNV | Missense_Mutation | novel | c.5353C>A | p.His1785Asn | p.H1785N | P42858 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
HTT | SNV | Missense_Mutation | c.2023N>A | p.Asp675Asn | p.D675N | P42858 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
HTT | SNV | Missense_Mutation | c.6970N>A | p.Glu2324Lys | p.E2324K | P42858 | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-AC-A2B8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | chemo | PD | |
HTT | SNV | Missense_Mutation | novel | c.5213N>C | p.Glu1738Ala | p.E1738A | P42858 | protein_coding | deleterious(0.01) | benign(0.226) | TCGA-AC-A62V-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Targeted Molecular therapy | denosumab | PD |
HTT | SNV | Missense_Mutation | novel | c.5776N>C | p.Asp1926His | p.D1926H | P42858 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
HTT | SNV | Missense_Mutation | rs758872041 | c.5263N>G | p.Ile1755Val | p.I1755V | P42858 | protein_coding | tolerated(0.09) | probably_damaging(0.919) | TCGA-C8-A132-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HTT | SNV | Missense_Mutation | rs41264725 | c.3205N>G | p.Met1069Val | p.M1069V | P42858 | protein_coding | tolerated(0.33) | benign(0) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3064 | HTT | DRUGGABLE GENOME | CUDC-907 | FIMEPINOSTAT | ||
3064 | HTT | DRUGGABLE GENOME | GNF-PF-4659 | CHEMBL584442 | ||
3064 | HTT | DRUGGABLE GENOME | PMID27376512-Compound-PG-11047 | |||
3064 | HTT | DRUGGABLE GENOME | GNF-PF-1852 | CHEMBL533293 | ||
3064 | HTT | DRUGGABLE GENOME | GNF-PF-67 | CHEMBL578512 | ||
3064 | HTT | DRUGGABLE GENOME | GNF-PF-2947 | CHEMBL581677 | ||
3064 | HTT | DRUGGABLE GENOME | GNF-PF-2356 | CHEMBL601547 | ||
3064 | HTT | DRUGGABLE GENOME | CID 94381 | CHEMBL374632 | ||
3064 | HTT | DRUGGABLE GENOME | FLUORESCEIN DIACETATE | FLUORESCEIN DIACETATE | ||
3064 | HTT | DRUGGABLE GENOME | TCMDC-124573 | CHEMBL525826 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |